Ascensia names leader for CGM business
By HME News Staff
Updated 10:26 AM CST, Tue February 6, 2024
TOKYO – PHC Holdings Corp., the parent company of Ascensia Diabetes Care, and Senseonics Holdings have announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of president of CGM at Ascensia Diabetes Care effective today, Feb. 6, 2024. Hansen will be responsible for the global commercialization and growth of the Eversense CGM, which is currently available in the U.S. and select European markets. “Eversense is a game-changer for people with diabetes and is an essential part of both Ascensia’s commitment to providing high-quality and life-enhancing products and PHC Group’s global business strategy,” said Koichiro Sato, COO of PHC Group. “Brian is ideally suited to lead our CGM business and enable us to realize the full potential of Eversense in the CGM market.” Hansen previously served as chief commercial officer for Tandem Diabetes Care, where he helped transform the company into a worldwide market leader, increasing patient utilization of Tandem products in the highly competitive insulin pump market. He has built a reputation for launching innovative products and overcoming commercial challenges with complex medical and regulatory landscapes. He has also held leadership positions at Adaptive Biotechnologies, Genoptix, Gen Probe and Thermo Fisher Scientific.
Comments